Abstract
Ebselen is an organo-selenium, highly hydrophobic compound that exhibits glutathion peroxidase-like activity. It is now in phase III trials in Japan for investigating its effect on ischemic stroke. We have developed an HPLC method for the determination of Ebselen at ambient temperature and applied it to a patented tablet formulation. The mobile phase composition, detection wavelength and chromatographic conditions were optimized. The optimum conditions are a Waters, C18, (25 cm × 4.6 mm, 5 μm) column, 1% acetic acid: methanol: propanol (40:50:10) (ν/ν) as the mobile phase at a flow rate of 0.7 mL min−1 and detection at 254 nm (internal standard: benzanilide). The method was validated and calibration curves were constructed depended on the ratios of Ebselen to benzanilide peak areas.
The concentration range for Ebselen was 0.82–11.71 μg mL−1, y=0.4021x + 0.0145 (r2=0.9993). Limit of quantification (LOQ) and limit of detection (LOD) were determined as 1.49 μg mL−1 and 0.45 μg mL−1 respectively, based on the blank signal and standard deviation of the peak areas of the minimum concentration of Ebselen. Recovery of Ebselen was found to be 98.70 ± 0.75% for 30 mg of tablet powder and 97.43 ± 0.78% for the 30 mg tablet form. The RSD was found to be 1.27% for 10 replicate injections of 50 μL. The ruggedness of the method was investigated by carrying out the same procedure on different days. There was no significant difference between 2 and 7 days time periods. The HPLC method is compared to a spectrophotometric method.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Muller A, Cadenas E, Graf P, Sies H (1984) Biochem Pharmacol 33:3235–3239
Parnham MJ, Leyck S, Kuhl P, Schalkwijk J, Van den Berg WB (1987) Int J Tissue React. 9:45–50
Li QJ, Bessems JGM, Commandeur JNM, Adams B, Vermeulen NPE (1994) Biochem Pharmacol 48(8):1631–1640
Baba M, Muruyama I, Masayasu H, 31 Oct 1996, JP Appl. 95/99, 273, 25 Apr 1995; 15pp. (Daiichi Pharmaceutical Co., Lmt.; Japan) PCT Int Appl WO 96 33, 712 (CI. A61K31/41)
Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H (1998) Stroke, 29:12–17
Parnham MJ, Sies H (2000) Exp. Opin. Invest. Drugs. 9 (3):607–619
Suziki Y, Umemura K (2000). Nippon Yakurigaku Zasshi, 116:379–384
Parnham MJ, 26 nov 1987, Appl. 20 May 1986, 5 pp. (Natterman, A., und Cie.G.m.b.H) Ger. Offen. DE 3,616,923 (CI. A61K31/095).
Maryuma I, Abeyama K, Masayasu H , 5 Mar 1998, JP Appl. 96/225, 512, 27 Aug 1996, 18 pp.(Ger) (Natterman, A., und Cie. G.m.b.H.) PCT Int. Appl. WO 98 08, 511 (CI.A61K31/41).
Vermulen NPE, Baldew GS, 13 Feb 1992, Appl. 06 Aug 1990; 3pp. (Natterman, A., und Cie. G.m.b.H.) Ger. Offen. DE 4,024,885 (CI. A61K31/555).
Muller A, Gabriel H, Sies H, Terlinden R, Fisher H, Römer AA (1988) Biochem. Pharm. 37(6):1103–1109
Kawai Y, Matsubayashi K (1996) Chem. Pharm. Bull. 44(8):1561–1566
Miller JN, Miller JC (2000) Statistics and Chemometrics for Analytical Chemistry 4Ed.; Pearson Education Lmt., Essex, England, pp. 116–118
Acknowledgements.
The authors wish to thank Aventis (Cologne, Germany) for their generous gift of Ebselen; the Research Fund of the University of the Marmara for their financial support (project SAG-6 Ebselen) and Prof. Dr. Mert Ülgen for providing benzanilide. The authors would like to thank Miss Nuray Yüktaş for her kind technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Revised: 18 June and 12 July 2004
Rights and permissions
About this article
Cite this article
Yalçın, G., Yılmaz, Ş. Determination of Ebselen by HPLC: Validation and Application of the Method. Chromatographia 60, 583–587 (2004). https://doi.org/10.1365/s10337-004-0423-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1365/s10337-004-0423-5